The FDA has signed off on a Phase 2 clinical trial evaluating Sorrento Therapeutics’ (SRNE +17.0%) abivertinib, a small molecule tyrosine kinase inhibitor, in hospitalized COVID-19 patients who have moderate-to-severe pulmonary symptoms.
On another note, it has inked an agreement with Agilent (A +1.3%) unit ACEA Therapeutics for exclusive rights to abivertinib for all indications world-wide except China.
https://seekingalpha.com/news/3592712-sorrento-on-go-mid-stage-study-of-abivertinib-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.